

CURRICULUM VITAE

Bahman Yousefi, Ph.D

Department of Clinical Biochemistry
Faculty of Medicine,
Tabriz University of Medical Sciences (TUMS),
Tabriz, Iran. Phone: +989149117624
Email: Bahmanusefi@gmail.com, yousefib@tbzmed.ac.ir

RESEARCH INTEREST

My research interest is focused on three main aspects of cancer biology: i) how oncogenic signaling drives cancer metabolic adaptation mechanisms and modifying ii) metabolic/signaling crosstalk between tumor cells and tumor microenvironment and iii) finding new strategies for cancer gene therapy. The final goal is to discover new molecules that can be exploited as therapeutic targets.

EDUCATIONS

- 2012 - 2016 Ph.D degree in Clinical Biochemistry, Tabriz University of Medical Sciences, Iran
Thesis: Role of the PPARs and its relation with PI3K/mTOR signaling pathway in doxorubicin resistant human chronic myeloid leukemia cells.
- 2009 – 2012 M.Sc. degree in Clinical Biochemistry, Tabriz University of Medical Sciences, Iran
Thesis: Study of PPAR α and ERK-MAPK signaling pathway effect on the $\Delta 6$ - and $\Delta 9$ -desaturase genes expression and fatty acid composition of HepG2 cell line
- 2004-2009 B.Sc. degree in Biology, University of Tabriz, Iran

RESPONSIBILITIES

- 2022- now Associate professor at Tabriz University of Medical Sciences (TUMS)
- 2016 - 2022 Assistant professor at TUMS
- 2018 - now Research Council Member, Molecular Medicine Research Center, TUMS
- 2019 - now Research Council Member, Immunology Research Center, TUMS

HONORS AND AWARDS

2020	The Best Young Researcher, honored by Iranian Ministry of Health and Medical Education
2018	2nd-ranked Best Researcher in Tabriz University of Medical Sciences (TUMS)
2015	Selected as top Young Researcher by Biochemical Society of Iran
2014	Selected as Top Talented Student Researcher in the University
2013- now	Member of Iran's National Elites Foundation

PROFISSIONAL ASSOSTIONS

- Biochemical Society of Iran
- Member of Iran's National Elites Foundation
- Iranian Society of Physiology and Pharmacology

MEMBER of EDITORIAL BOARD

2021	Invited as Guest Editor, <i>Biochimie</i> ; (Impact Factor: 4.08); Published by Elsevier
Link:	https://www.sciencedirect.com/science/article/abs/pii/S030090842200267X

JOURNAL REVIEWER

Reviewing more than 100 papers for ISI peer reviewed journals for example:

Biomaterials (IF: 15.3), *Redox Biology* (IF:11.8), *Journal of Control Release* (IF:11.4), *Biomedicine & Pharmacotherapy* (IF:6.5), , *European Journal of Pharmacology* (IF:4.4), *Biochimie* (IF: 4.2), *Critical Reviews in Food Science and Nutrition* (IF: 11.2), *Journal of Cellular Physiology*(IF:6.7), *DNA Repair* (IF:4.2), *Experimental Cell Research* (IF:3.9), *Chemico-Biological Interactions* (IF:5.1), *Gene* (IF:5.2).

PUBLICATIONS

1. M Vaghari-Tabari, N Targhazeh, S Moein, D Qujeq, F Alemi, M Majidina, **B Yousefi** . From inflammatory bowel disease to colorectal cancer: what's the role of miRNAs? *Cancer Cell International* 22 (1), 1-21. 2022.
2. Sadoughi F, Mirsafaei L, Dana PM, Hallajzadeh J, Asemi Z, Mansournia MA, Montazer M, Hosseinpour M, **Yousefi B**. The role of DNA damage response in chemo-and radio- resistance of

- cancer cells: Can DDR inhibitors solve the problem? *DNA repair*. 2021;101:103074.
3. Homayoonfal M, Asemi Z, **Yousefi B** . Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis. *Cell Mol Biol Lett*. Mar 2;27(1):21. 2022.
 4. Mihanfar A, Darband SG, Sadighparvar S, Kaviani M, Mirza-Aghazadeh-Attari M, **Yousefi B**, Majidinia M. In vitro and in vivo anticancer effects of syringic acid on colorectal cancer: Possible mechanistic view. *Chemico-Biological Interactions*. 2021;337:109337.
 5. Maleki M, Golchin A, Javadi S, Khelghati N, Morovat P, Asemi Z, Alemi F, Vaghari-Tabari M, **Yousefi B**, Majidinia M. Role of exosomal miRNA in chemotherapy resistance of Colorectal cancer: A systematic review. *Chemical Biology & Drug Design*. 2021.
 6. Sadoughi F, Hallajzadeh J, Asemi Z, Mansournia MA, Alemi F, **Yousefi B**. Signaling pathways involved in cell cycle arrest during the DNA breaks. *DNA repair*. 2021;98:103047.
 7. Sadoughi F, Maleki Dana P, Asemi Z, **Yousefi B**. Targeting microRNAs by curcumin: implication for cancer therapy. *Critical Reviews in Food Science and Nutrition*. 2021:1-12.
 8. The role of polyphenols in overcoming cancer drug resistance: a comprehensive review. Maleki Dana P, Sadoughi F, Asemi Z, **Yousefi B**. *Cell Mol Biol Lett*. 2022 Jan 3;27(1):1
 9. Malakoti F, Alemi F, Younesi S, Majidinia M, **Yousefi B**, Morovat P, Khelghati N, Maleki M, Karimian A, Asemi Z. The cross-talk between signaling pathways, noncoding RNAs and DNA damage response: Emerging players in cancer progression. *DNA repair*. 2021;98:103036.
 10. A Karimian, M Majidinia, A Moliani, F Alemi, Z Asemi, **B Yousefi***, et al. The modulatory effects of two bioflavonoids, quercetin and thymoquinone on the expression levels of DNA damage and repair genes in human breast, lung and prostate cancer cell lines. *Pathology-Research and Practice*, 154143.
 11. F Malakoti, E Mohammadi, M Akbari Oryani, D Shanebandi, **B Yousefi***, et al. Polyphenols and inflammatory bowel disease: Natural products with therapeutic effects? *Critical Reviews in Food Science and Nutrition*, 1-17. 2022.
 12. Valizadeh A, Sayadmanesh A, Asemi Z, Alemi F, Mahmoodpoor A, **Yousefi B**. Regulatory Roles of the Notch Signaling Pathway in Liver Repair and Regeneration: A Novel Therapeutic Target. *Current Medicinal Chemistry*. 2021;28(41):8608-26.
 13. Vaghari-Tabari M, Mohammadzadeh I, Qujeq D, Majidinia M, Alemi F, Younesi S, Mahmoodpoor A, Maleki M, **Yousefi B***, Asemi Z. Vitamin D in respiratory viral infections: a key immune modulator? *Critical Reviews in Food Science and Nutrition*. 2021:1-16.
 14. Maleki Dana P, Sadoughi F, Mirzaei H, Asemi Z, **Yousefi B** . DNA damage response and repair in the

- development and treatment of brain tumors. *Eur J Pharmacol.* 2022;Apr 14;924:174957.
15. N Targhazeh, KJ Hutt, AL Winship, R Reiter, **B Yousefi** . Melatonin as an oncostatic agent: Review of the modulation of tumor microenvironment and overcoming multidrug resistance. *Biochimie.* 2022.
 16. Pazhooh RD, Farnood PR, Asemi Z, Mirsafaei L, **Yousefi B**, Mirzaei H. mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy. *DNA repair.* 2021;104:103142.
 17. Ni G, **Yousefi B**, Qujeq D, Marjani A, Asadi J, Wang Z, Mir SM. Melatonin and doxorubicin co-delivered via a functionalized graphene-dendrimeric system enhances apoptosis of osteosarcoma cells. *Materials Science and Engineering: C.* 2021;119:111554.
 18. Mohammadi E, Sadoughi F, Younesi S, Karimian A, Asemi Z, Farsad-Akhtar N, Jahanbakhshi F, Jamilian H, **Yousefi B**. The molecular mechanism of nuclear signaling for degradation of cytoplasmic DNA: Importance in DNA damage response and cancer. *DNA repair.* 2021;103:103115.
 19. Mirza-Aghazadeh-Attari M, Recio MJ, Darband SG, Kaviani M, Safa A, Mihanfar A, Sadighparvar S, Karimian A, Alemi F, Majidinia M. DNA damage response and breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition. *DNA repair.* 2021;98:103032.
 20. Mihanfar A, **Yousefi B**, Darband SG, Sadighparvar S, Kaviani M, Majidinia M. Melatonin increases 5-fluorouracil-mediated apoptosis of colorectal cancer cells through enhancing oxidative stress and downregulating survivin and XIAP. *BioImpacts: BI.* 2021;11(4):253.
 21. Mihanfar A, Targhazeh N, Sadighparvar S, Darband SG, Majidinia M, **Yousefi B**. Doxorubicin loaded magnetism nanoparticles based on cyclodextrin dendritic-graphene oxide inhibited MCF-7 cell proliferation. *Biomolecular Concepts.* 2021;12(1):8-15.
 22. Maleki M, Golchin A, Alemi F, Younesi S, Asemi Z, Javadi S, Khiavi PA, Soleinmapour J, **Yousefi B**. Cytotoxicity and apoptosis of nanoparticles on osteosarcoma cells using doxorubicin and methotrexate: A systematic review. *European Journal of Pharmacology.* 2021;904:174131.
 23. Maleki Dana P, Sadoughi F, Mansournia MA, Mirzaei H, Asemi Z, **Yousefi B**. Targeting Wnt signaling pathway by polyphenols: implication for aging and age-related diseases. *Biogerontology.* 2021;22(5):479-94.
 24. Hosseini F, Alemi F, Malakoti F, Mahmoodpoor A, Younesi S, **Yousefi B**, Asemi Z. Targeting Wnt/ β -catenin signaling by microRNAs as a therapeutic approach in chemoresistant osteosarcoma. *Biochemical Pharmacology.* 2021;193:114758.
 25. Homayoonfal M, Asemi Z, **Yousefi B**. Targeting long non coding RNA by natural products: Implications for cancer therapy. *Critical Reviews in Food Science and Nutrition.* 2021:1-29.
 26. Homayoonfal M, Asemi Z, **Yousefi B**. Targeting microRNAs with thymoquinone: a new approach for

- cancer therapy. *Cellular & Molecular Biology Letters*. 2021;26(1):1-22.
27. Farnood PR, Pazhooh RD, Asemi Z, **Yousefi B**. DNA damage response and repair in pancreatic cancer development and therapy. *DNA repair*. 2021;103:103116.
 28. Alemi F, Raei Sadigh A, Malakoti F, Elhaei Y, Ghaffari SH, Maleki M, Asemi Z, **Yousefi B**, Targhazeh N, Majidinia M. Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk. *Journal of Cellular Physiology*. 2021.
 29. Vaghari-Tabari M, Majidinia M, Moein S, Qujeq D, Asemi Z, Alemi F, Mohamadzadeh R, Targhazeh N, Safa A, **Yousefi B**. MicroRNAs and colorectal cancer chemoresistance: New solution for old problem. *Life Sciences*. 2020;259:118255.
 30. A, Majidina M, Safa A, Yosefi B. miRNA-29a reverses P-glycoprotein-mediated drug resistance and inhibits proliferation via up-regulation of PTEN in colon cancer cells. *European Journal of Pharmacology*. 2020;880:173138.
 31. Sanches-Silva A, Testai L, Nabavi SF, Battino M, Devi KP, Tejada S, Sureda A, Xu S, **Yousefi B**, Majidinia M. Therapeutic potential of polyphenols in cardiovascular diseases: Regulation of mTOR signaling pathway. *Pharmacological research*. 2020;152:104626.
 32. Salamat A, Majidinia M, Asemi Z, Sadeghpour A, Oskoi MA, Shanebandi D, Alemi F, Mohammadi E, Karimian A, Targhazeh N. Modulation of telomerase expression and function by miRNAs: Anti-cancer potential. *Life Sciences*. 2020;259:118387.
 33. Sadighparvar S, Darband SG, **Yousefi B**, Kaviani M, Ghaderi-Pakdel F, Mihanfar A, Babaei G, Mobaraki K, Majidinia M. Combination of quercetin and exercise training attenuates depression in rats with 1, 2-dimethylhydrazine-induced colorectal cancer: Possible involvement of inflammation and BDNF signalling. *Experimental physiology*. 2020;105(9):1598-609.
 34. Reiter R, Hallajzadeh J, Asemi Z, Mansournia M, **Yousefi B**. Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes. *IUBMB Life*. 2020.
 35. Mirza-Aghazadeh-Attari M, Reiter RJ, Rikhtegar R, Jalili J, Hajalioghli P, Mihanfar A, Majidinia M, **Yousefi B**. Melatonin: An atypical hormone with major functions in the regulation of angiogenesis. *IUBMB life*. 2020;72(8):1560-84.
 36. Mirza-Aghazadeh-Attari M, Mohammadzadeh A, Mostavafi S, Mihanfar A, Ghazizadeh S, Sadighparvar S, Gholamzadeh S, Majidinia M, **Yousefi B**. Melatonin: An important anticancer agent in colorectal cancer. *Journal of cellular physiology*. 2020;235(2):804-17.
 37. Mirza-Aghazadeh-Attari M, Ekrami EM, Aghdas SAM, Mihanfar A, Hallaj S, **Yousefi B**, Safa A, Majidinia M. Targeting PI3K/Akt/mTOR signaling pathway by polyphenols: Implication for cancer

- therapy. *Life sciences*. 2020;255:117481.
38. Maleki M, Zarezadeh R, Nouri M, Sadigh AR, Pouremamali F, Asemi Z, Kafil HS, Alemi F, **Yousefi B**. Graphene Oxide: A Promising Material for Regenerative Medicine and Tissue Engineering. *Biomolecular Concepts*. 2020;11(1):182-200.
 39. Maleki Dana P, Reiter RJ, Hallajzadeh J, Asemi Z, Mansournia MA, **Yousefi B**. Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes. *Iubmb Life*. 2020;72(11):2355-65.
 40. Majidinia M, Mirza-Aghazadeh-Attari M, Rahimi M, Mihanfar A, Karimian A, Safa A, **Yousefi B**. Overcoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons. *IUBMB life*. 2020;72(5):855-71.
 41. Majidinia M, Mir SM, Mirza-Aghazadeh-Attari M, Asghari R, Kafil HS, Safa A, Mahmoodpoor A, **Yousefi B**. MicroRNAs, DNA damage response and ageing. *Biogerontology*. 2020;21(3):275-91.
 42. Majidinia M, Karimian A, Alemi F, **Yousefi B**, Safa A. Targeting miRNAs by polyphenols: Novel therapeutic strategy for aging. *Biochemical pharmacology*. 2020;173:113688.
 43. Khelghati N, Rasmi Y, Farahmandan N, Sadeghpour A, Mir SM, Karimian A, **Yousefi B**. Hyperbranched polyglycerol β -cyclodextrin as magnetic platform for optimization of doxorubicin cytotoxic effects on Saos-2 bone cancerous cell line. *Journal of Drug Delivery Science and Technology*. 2020;57:101741.
 44. Karimian A, Gorjizadeh N, Alemi F, Asemi Z, Azizian K, Soleimanpour J, Malakouti F, Targhazeh N, Majidinia M, **Yousefi B**. CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases. *Life Sciences*. 2020;259:118165.
 45. Hallajzadeh J, Maleki Dana P, Mobini M, Asemi Z, Mansournia MA, Sharifi M, **Yousefi B**. Targeting of oncogenic signaling pathways by berberine for treatment of colorectal cancer. *Medical Oncology*. 2020;37(6):1-9.
 46. Halajzadeh J, Dana PM, Asemi Z, Mansournia MA, **Yousefi B**. An insight into the roles of piRNAs and PIWI proteins in the diagnosis and pathogenesis of oral, esophageal, and gastric cancer. *Pathology-Research and Practice*. 2020;216(10):153112.
 47. Darband SG, Sadighparvar S, **Yousefi B**, Kaviani M, Mobaraki K, Majidinia M. Combination of exercise training and L-arginine reverses aging process through suppression of oxidative stress, inflammation, and apoptosis in the rat heart. *Pflügers Archiv-European Journal of Physiology*. 2020;472(2):169-78.
 48. Darband SG, Sadighparvar S, **Yousefi B**, Kaviani M, Ghaderi-Pakdel F, Mihanfar A, Rahimi Y,

- Mobaraki K, Majidinia M. Quercetin attenuated oxidative DNA damage through NRF2 signaling pathway in rats with DMH induced colon carcinogenesis. *Life Sciences*. 2020;253:117584.
49. Danaii S, Abolhasani R, Soltani-Zangbar MS, Zamani M, Mehdizadeh A, Amanifar B, **Yousefi B**, Nazari M, Pourlak T, Hajialiloo M. Immunological and oxidative stress biomarkers in Ankylosing spondylitis patients. *Gene Reports*. 2020;18:100574.
 50. Dana PM, Taghavipour M, Mirzaei H, **Yousefi B**, Moazzami B, Chaichian S, Asemi Z. Circular RNA as a potential diagnostic and/or therapeutic target for endometriosis. *Biomarkers in Medicine*. 2020;14(13):1277-87.
 51. Dana PM, Sadoughi F, Hallajzadeh J, Asemi Z, Mansournia MA, **Yousefi B**, Momen-Heravi M. An insight into the sex differences in COVID-19 patients: what are the possible causes? *Prehospital and disaster medicine*. 2020;35(4):438-41.
 52. Bazavar M, Fazli J, Valizadeh A, Ma B, Mohammadi E, Asemi Z, Alemi F, Maleki M, Xing S, **Yousefi B**. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells. *Pathology-Research and Practice*. 2020;216(11):153176.
 53. Amirani E, Hallajzadeh J, Asemi Z, Mansournia MA, **Yousefi B**. Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy. *International journal of biological macromolecules*. 2020;164:456-67.
 54. Alemi F, Zarezadeh R, Sadigh AR, Hamishehkar H, Rahimi M, Majidinia M, Asemi Z, Ebrahimi-Kalan A, **Yousefi B**, Rashtchizadeh N. Graphene oxide and reduced graphene oxide: Efficient cargo platforms for cancer theranostics. *Journal of Drug Delivery Science and Technology*. 2020;60:101974.
 55. Ahmadi Y, Mahmoudi N, **Yousefi B**, Karimian A. The effects of statins with a high hepatoselectivity rank on the extra-hepatic tissues; new functions for statins. *Pharmacological Research*. 2020;152:104621.
 56. Abolghasemi M, Tehrani SS, Yousefi T, Karimian A, Mahmoodpoor A, Ghamari A, Jadidi-Niaragh F, Yousefi M, Kafil HS, Bastami M. MicroRNAs in breast cancer: Roles, functions, and mechanism of actions. *Journal of cellular physiology*. 2020;235(6):5008-29.
 57. **Yousefi B**, Mohammadlou M, Abdollahi M, Salek Farrokhi A, Karbalaei M, Keikha M, Kokhaei P, Valizadeh S, Rezaeiemanesh A, Arabkari V. Epigenetic changes in gastric cancer induction by *Helicobacter pylori*. *Journal of cellular physiology*. 2019;234(12):21770-84.
 58. Valizadeh A, Majidinia M, Samadi-Kafil H, Yousefi M, **Yousefi B**. The roles of signaling pathways in liver repair and regeneration. *Journal of Cellular Physiology*. 2019;234(9):14966-74.
 59. Alemi F, Malakoti F, Vaghari-Tabari M, Soleimanpour J, Shabestani N, Sadigh AR, Khelghati N,

- Asemi Z, Ahmadi Y, **Yousefi B** . DNA damage response signaling pathways as important targets for combination therapy and chemotherapy sensitization in osteosarcoma. *J Cell Physiol*. 2022 Apr 5. doi: 10.1002/jcp.30721. 2022.
60. Tabari FS, Karimian A, Parsian H, Rameshknia V, Mahmoodpour A, Majidinia M, Maniati M, **Yousefi B**. The roles of FGF21 in atherosclerosis pathogenesis. *Reviews in Endocrine and Metabolic Disorders*. 2019;20(1):103-14.
 61. Shafiei-Irannejad V, Rahimi M, Zarei M, Dinparast-Isaleh R, Bahrambeigi S, Alihemmati A, Shojaei S, Ghasemi Z, **Yousefi B**. Polyelectrolyte carboxymethyl cellulose for enhanced delivery of doxorubicin in MCF7 breast cancer cells: Toxicological evaluations in mice model. *Pharmaceutical research*. 2019;36(5):1-17.
 62. Saadatian Z, Nariman-Saleh-Fam Z, Bastami M, Mansoori Y, Khaheshi I, Parsa SA, Daraei A, Vahed SZ, **Yousefi B**, Kafil HS. Dysregulated expression of STAT1, miR-150, and miR- 223 in peripheral blood mononuclear cells of coronary artery disease patients with significant or insignificant stenosis. *Journal of cellular biochemistry*. 2019;120(12):19810-24.
 63. Rostami N, Nikkhoo A, Ajjoolabady A, Azizi G, Hojjat-Farsangi M, Ghalamfarsa G, **Yousefi B**, Yousefi M, Jadidi-Niaragh F. S1PR1 as a novel promising therapeutic target in cancer therapy. *Molecular Diagnosis & Therapy*. 2019;23(4):467-87.
 64. Pourakbari, Parhizkar, Soltani-Zangbar, Samadi, Zamani, Aghebati-Maleki, Motavalli, Mahmoodpoor, Jadidi-Niaragh, **Yousefi B**, Samadi Kafil, Hojjat-Farsangi, Danaii, Yousefi. Preeclampsia-Derived Exosomes Imbalance the Activity of Th17 and Treg in PBMCs from Healthy Pregnant Women *Reprod Sci*. 2022 Sep 26.
 65. Rahimi M, Karimian R, Noruzi EB, Ganbarov K, Zarei M, Kamounah FS, **Yousefi B**, Bastami M, Yousefi M, Kafil HS. Needle-shaped amphoteric calix [4] arene as a magnetic nanocarrier for simultaneous delivery of anticancer drugs to the breast cancer cells. *International journal of nanomedicine*. 2019;14:2619.
 66. Mohammadzadeh A, Mirza-Aghazadeh-Attari M, Hallaj S, Saei AA, Alivand MR, Valizadeh A, **Yousefi B**, Majidinia M. Crosstalk between P53 and DNA damage response in ageing. *DNA repair*. 2019;80:8-15.
 67. M Vaghari-Tabari, P Hassanpour, F Sadeghsoltani, F Malakoti, F Alemi, **B Yousefi** . CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer. *Cellular & Molecular Biology Letters* 27 (1), 1-29. 2022.
 68. Mirza-Aghazadeh-Attari M, Ostadian C, Saei AA, Mihanfar A, Darband SG, Sadighparvar S, Kaviani

- M, Kafil HS, **Yousefi B**, Majidinia M. DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies. *DNA repair*. 2019;80:59-84.
69. Mirza-Aghazadeh-Attari M, Mohammadzadeh A, **Yousefi B**, Mihanfar A, Karimian A, Majidinia M. 53BP1: A key player of DNA damage response with critical functions in cancer. *DNA repair*. 2019;73:110-9.
70. Mirza-Aghazadeh-Attari M, Mohammadzadeh A, Adib A, Darband SG, Sadighparvar S, Mihanfar A, Majidinia M, **Yousefi B**. Melatonin-mediated regulation of autophagy: making sense of double-edged sword in cancer. *Journal of cellular physiology*. 2019;234(10):17011- 22.
71. Mashayekhi S, **Yousefi B**, Tohidi E, Darband SG, Mirza-Aghazadeh-Attari M, Sadighparvar S, Kaviani M, Shafiei-Irannejad V, Kafil HS, Karimian A. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin- resistance leukemia cancer cells to treatment. *Journal of Cellular Biochemistry*. 2019;120(9):15719-29.
72. Majidinia M, Bishayee A, **Yousefi B**. Polyphenols: Major regulators of key components of DNA damage response in cancer. *DNA repair*. 2019;82:102679.
73. Karimian A, Parsian H, Majidinia M, Rahimi M, Mir SM, Kafil HS, Shafiei-Irannejad V, Kheyrollah M, Ostadi H, **Yousefi B**. Nanocrystalline cellulose: Preparation, physicochemical properties, and applications in drug delivery systems. *International journal of biological macromolecules*. 2019;133:850-9.
74. Karimian A, Mir SM, Parsian H, Refieyan S, Mirza-Aghazadeh-Attari M, **Yousefi B**, Majidinia M. Crosstalk between Phosphoinositide 3-kinase/Akt signaling pathway with DNA damage response and oxidative stress in cancer. *Journal of Cellular Biochemistry*. 2019;120(6):10248-72.
75. Karimian A, Azizian K, Parsian H, Rafieian S, Shafiei-Irannejad V, Kheyrollah M, Yousefi M, Majidinia M, **Yousefi B**. CRISPR/Cas9 technology as a potent molecular tool for gene therapy. *Journal of cellular physiology*. 2019;234(8):12267-77.
76. Jahanban-Esfahlan R, Seidi K, Majidinia M, Karimian A, **Yousefi B**, Nabavi SM, Astani A, Berindan-Neagoe I, Gulei D, Fallarino F. Toll-like receptors as novel therapeutic targets for herpes simplex virus infection. *Reviews in Medical Virology*. 2019;29(4):e2048.
77. Tehrani SS, Karimian A, Parsian H, Majidinia M, **Yousefi B**. Multiple functions of long non-coding RNAs in oxidative stress, DNA damage response and cancer progression. *Journal of cellular biochemistry*. 2018;119(1):223-36.
78. Shafiei-Irannejad V, Samadi N, Salehi R, **Yousefi B**, Rahimi M, Akbarzadeh A, ZarghamiN. Reversion of multidrug resistance by co-encapsulation of doxorubicin and metformin in poly (lactide-

- co-glycolide)-d- α -tocopheryl polyethylene glycol 1000 succinate nanoparticles. *Pharmaceutical research*. 2018;35(6):1-13.
79. Alemi, Maleki, Mir, Ebrahimi-Kalan, Zarei, **Yousefi B**, Rashtchizadeh Synthesis, characterization, and evaluation of pH-sensitive doxorubicin-loaded functionalized graphene oxide in osteosarcoma cells. *BioImpacts*. 2018;233(10):6455-69. doi: 10.34172/bi.2022.23820
 80. Mirza-Aghazadeh-Attari M, Darband SG, Kaviani M, Mihanfar A, Attari JA, **Yousefi B**, Majidinia M. DNA damage response and repair in colorectal cancer: Defects, regulation and therapeutic implications. *DNA repair*. 2018;69:34-52.
 81. Malakoti, Alemi, Jafari Yeganeh, Hosseini, Shabestani, Samemaleki, Maleki, Fathi Daneshvar, Montazer, **Yousefi B**. Long noncoding RNA SNHG7-miRNA-mRNA axes crosstalk with oncogenic signaling pathways in human cancers. *Chem Biol Drug Des*. 2022 Aug 22. doi: 10.1111/cbdd.14118.
 82. Majidinia M, Reiter RJ, Shakouri SK, **Yousefi B**. The role of melatonin, a multitasking molecule, in retarding the processes of ageing. *Ageing research reviews*. 2018;47:198-213.
 83. Majidinia M, Reiter RJ, Shakouri SK, Mohebbi I, Rastegar M, Kaviani M, Darband SG, Jahanban-Esfahlan R, Nabavi SM, **Yousefi B**. The multiple functions of melatonin in regenerative medicine. *Ageing research reviews*. 2018;45:33-52.
 84. Ainaz Mihanfar, **Yousefi B**, Bitra Azizzadeh & Maryam Majidinia. Interactions of melatonin with various signaling pathways: implications for cancer therapy. *Cancer Cell International* volume 22, Article number: 420 (2022)
 85. Majidinia M, Aghazadeh J, Jahanban-Esfahlan R, **Yousefi B**. The roles of Wnt/ β -catenin pathway in tissue development and regenerative medicine. *Journal of cellular physiology*. 2018;233(8):5598-612.
 86. Khanzadeh T, Hagh MF, Talebi M, **Yousefi B**, Azimi A, Baradaran B. Investigation of BAX and BCL2 expression and apoptosis in a resveratrol-and prednisolone-treated human T- ALL cell line, CCRF-CEM. *Blood research*. 2018;53(1):53-60.
 87. Jahanban-Esfahlan R, Seidi K, Banimohamad-Shotorbani B, Jahanban-Esfahlan A, **Yousefi B**. Combination of nanotechnology with vascular targeting agents for effective cancer therapy. *Journal of cellular physiology*. 2018;233(4):2982-92.
 88. Jahanban-Esfahlan R, de la Guardia M, Ahmadi D, **Yousefi B**. Modulating tumor hypoxia by nanomedicine for effective cancer therapy. *Journal of cellular physiology*. 2018;233(3):2019-31.
 89. Darband SG, Mirza-Aghazadeh-Attari M, Kaviani M, Mihanfar A, Sadighparvar S, **Yousefi B**, Majidinia M. Exosomes: natural nanoparticles as bio shuttles for RNAi delivery. *Journal of Controlled Release*. 2018;289:158-70.

90. Darband SG, Kaviani M, **Yousefi B**, Sadighparvar S, Pakdel FG, Attari JA, Mohebbi I, Naderi S, Majidinia M. Quercetin: a functional dietary flavonoid with potential chemo- preventive properties in colorectal cancer. *Journal of Cellular Physiology*. 2018;233(9):6544- 60.
91. Azimi A, Majidinia M, Shafiei-Irannejad V, Jahanban-Esfahlan R, Ahmadi Y, Karimian A, mostafa Mir S, Karami H, **Yousefi B**. Suppression of p53R2 gene expression with specific siRNA sensitizes HepG2 cells to doxorubicin. *Gene*. 2018;642:249-55.
92. **Yousefi B**, Azimi A, Majidinia M, Shafiei-Irannejad V, Badalzadeh R, Baradaran B, Zarghami N, Samadi N. Balaglitazone reverses P-glycoprotein-mediated multidrug resistance via upregulation of PTEN in a PPAR γ -dependent manner in leukemia cells. *Tumor Biology*. 2017;39(10):1010428317716501.
93. Majidinia M, **Yousefi B**. DNA repair and damage pathways in breast cancer development and therapy. *DNA repair*. 2017;54:22-9.
94. Majidinia M, **Yousefi B**. Breast tumor stroma: A driving force in the development of resistance to therapies. *Chemical biology & drug design*. 2017;89(3):309-18.
95. Karimaian A, Majidinia M, Baghi HB, **Yousefi B**. The crosstalk between Wnt/ β -catenin signaling pathway with DNA damage response and oxidative stress: Implications in cancer therapy. *Dna Repair*. 2017;51:14-9.
96. Badalzadeh R, Baradaran B, Alihemmati A, **Yousefi B**, Abbaszadeh A. Troxerutin preconditioning and ischemic postconditioning modulate inflammatory response after myocardial ischemia/reperfusion injury in rat model. *Inflammation*. 2017;40(1):136-43.
97. **Yousefi B**, Zarghami N, Samadi N, Majidinia M. Peroxisome proliferator-activated receptors and their ligands in cancer drug-resistance: opportunity or challenge. *Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents)*. 2016;16(12):1541-8.
98. **Yousefi B**, Samadi N, Baradaran B, Shafiei-Irannejad V, Zarghami N. Peroxisome proliferator-activated receptor ligands and their role in chronic myeloid leukemia: Therapeutic strategies. *Chemical biology & drug design*. 2016;88(1):17-25.
99. Majidinia M, **Yousefi B**. DNA damage response regulation by microRNAs as a therapeutic target in cancer. *DNA repair*. 2016;47:1-11.
100. Karimian A, Ahmadi Y, **Yousefi B**. Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. *DNA repair*. 2016;42:63-71.
101. Montazami N, Kheirandish M, Majidi J, Yousefi M, **Yousefi B**, Mohamadnejad L, Shanebandi D, Estiar M, Khaze V, Mansoori B. siRNA-mediated silencing of MDR1 reverses the resistance to

- oxaliplatin in SW480/OxR colon cancer cells. *Cellular and Molecular Biology*. 2015;61(2):98-103.
102. **Yousefi B**, Samadi N, Ahmadi Y. Akt and p53R2, partners that dictate the progression and invasiveness of cancer. *DNA repair*. 2014;22:24-9.
 103. **Yousefi B**, Rahmati M, Ahmadi Y. The roles of p53R2 in cancer progression based on the new function of mutant p53 and cytoplasmic p21. *Life sciences*. 2014;99(1-2):14-7.
 104. Saliyani N, Darabi M, **Yousefi B**, Baradaran B, Khaniani MS, Darabi M, Shaaker M, Mehdizadeh A, Naji T, Hashemi M. PPAR γ agonist-induced alterations in $\Delta 6$ -desaturase and stearyl-CoA desaturase 1: Role of MEK/ERK1/2 pathway. *World journal of hepatology*. 2013;5(4):220.
 105. Vaghari-Tabari M, Moein S, Alipourian A, Qujeq D, Malakoti F, Alemi F, **Yousefi B**, Khazaie S. Melatonin and inflammatory bowel disease: From basic mechanisms to clinical application. *Biochimie*. 2022 Dec 16:S0300-9084(22)00331-5.
 106. Malakoti F, Zare F, Zarezadeh R, Raei Sadigh A, Sadeghpour A, Majidinia M, Yousefi B, Alemi F. The role of melatonin in bone regeneration: A review of involved signaling pathways. *Biochimie*. 2022 Nov;202:56-70.
 107. **Yousefi B**, Darabi M, Baradaran B, Khaniani MS, Rahbani M, Darabi M, Fayezi S, Mehdizadeh A, Saliyani N, Shaaker M. Inhibition of MEK/ERK1/2 signaling affects the fatty acid composition of HepG2 human hepatic cell line. *BioImpacts: BI*. 2012;2(3):145.
 108. F Malakoti, N Targhazeh, E Abadifard, R Zarezadeh, S Samemaleki, **B Yousefi** . DNA repair and damage pathways in mesothelioma development and therapy. *Cancer Cell International* 22 (1), 1-12. 2022.
 109. Homayoonfal M, Asemi Z, **Yousefi B**. Potential anticancer properties and mechanisms of thymoquinone in osteosarcoma and bone metastasis. *Cell Mol Biol Lett*. 2022 Mar 2;27(1):21.
 110. Maleki Dana P, Sadoughi F, Asemi Z, **Yousefi B** . The role of polyphenols in overcoming cancer drug resistance: a comprehensive review. *Cell Mol Biol Lett*. 2022;Jan 3;27(1):1

HOLDING WORKSHOPS

Holding workshop on biomedical research methods in 21st Internaral Physiology and Pharmacology Congress (Iran) including:

- Western blotting,
- Electrophoresis
- qRT-PCR
- Cell culture

REFEREES

- Russel J. Reiter, Chair and Professor
Department of Cellular & Structural Biology,
University of Texas, Health Science Center San Antonio
Email: reiter@uthscsa.edu

- Prof. Behzad Baradaran, Chair and Professor
Immunology Research Center,
Tabriz University of Medical Sciences Tabriz, Iran
Email: behzad_im@yahoo.com

- A/Prof. Maryam Majidinia, Chair and Professor
Solid Tumor Research Center,
Urmia University of Medical Sciences Urmia, Iran
Email: majidinia25@gmail.com